［1］Spanheimer PM，Carr JC，Thomas A，et al.The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer［J］.Am J Surg,2013,206(1)：2-7.
［2］Yu Y，Xiang H，He XM，et al.Predictive factors determining neoadjuvant chemotherapy outcomes in breast cancer-a single center experience［J］.Asian Pac J Cancer Prev，2013，14(4)：2401-2406.
［3］Zhou LY，Shi YH，Wang X，et al.Efficacy of neoadjuvant chemotherapy in patients with triple-negative breast cancer and prognostic analysis［J］.Tumor，2014,34(5)：454-457.［周立艳,史业辉,汪旭，等.三阴性乳腺癌新辅助化疗疗效及预后分析［J］.肿瘤,2014,34(5)：454-457.］
［4］Kawajiri H,Takashima T,Aomatsu N,et al.Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer［J］.Oncol Lett,2014,7(3)：663-668.
［5］Hammond ME，Hayes DF，Dowsett M，et al．American society of clinical oncology／college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer［J］．Arch Pathol Lab Med,2010,134(6)：907-922．
［6］Hu XC,Wang BY,Shao ZM.The comparison of 《St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011》 and guidelines for chinese anti-cancer association，committee of breast cancer society［J］．Chin J Breast Dis（Electronic Version)，2011，5(4)：404-407．［胡夕春，王碧芸，邵志敏．2011年《St．Gallen早期乳腺癌初治治疗国际专家共识》与中国抗癌协会乳腺癌专业委员会指南之比较［J］．中华乳腺病杂志(电子版)，2011，5(4)：404-407．］
［7］Sun B,Song ST,Jiang ZF,et al.Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breastcancer patients［J］.Chin J Oncol,2013,35(1)：38-42.［孙冰,宋三泰,江泽飞,等.乳腺癌新辅助化疗病理完全缓解的影响因素分析［J］.中华肿瘤杂志,2013,35(1)：38-42.］
［8］Straver ME,Van Adrichem JC,Rutgers EJ,et al.Neoadjuvant systemictherapy in patients with operable primary breast cancer：more benefits than breast-conserving therapy［J］.Ned Tijdschr Geneeskd,2008,152(46)：2519-2525.
［9］Gao DZ,Fu QY,Zhang Q,et al.The effect of 6 cycles ET neoadjuvant chemotherapy regimen on breast cancer and its influencing factors［J］.Chin J General Surg,2012,27(5)：398-401.［高德宗,傅勤烨,张强,等.乳腺癌6周期ET方案新辅助化疗的疗效及其影响因素分析［J］.中华普通外科杂志,2012,27(5)：398-401.］
［10］Weiss A，Lee KC，Romero Y，et al.Calcifications on mammogram do not correlate with tumor size after neoadjuvant chemotherapy［J］.Ann Surg Oncol，2014，21(10)：3310-3316.
［11］Zhang HT,Zhao YB,Song PJ,et al.Application of molybdenum target mammography to evaluation of neoadjuvant chemotherapy in breast cancer［J］.Military Medical Sciences,2012，36（8）：616-618.［张洪涛,赵一冰,宋培记,等.钼靶乳腺摄像在乳腺癌新辅助化疗疗效评价中的应用［J］.军事医学,2012,36（8）：616-618.］
［12］Jiang L,Ma T,Moran MS,et al.Mammographic features are associated with clinicopathological characteristics in invasive breast cancer［J］.Anticancer Res,2011,31(6)：2327-2334.
［13］Holmberg L,Wong YN,Tabár L,et al.Mammography casting-type calcification and risk of local recurrence in DCIS：analyses from a randomised study［J］.Br J Cancer,2013,108(4)：812-819.
［14］Krishnan Y，Alawadhi SA，P SS，et al.Pathological responses and long-term outcome analysis after neoadjuvant chemotheraphy in breast cancer patients from Kuwait over a period of 15 years［J］.Ann Saudi Med，2013，33(5)：443-450.
［15］Han S,Kim J,Lee J,et al.Comparison of 6 cycles versus 4 cycles of neoadjuvant epirubicin plus docetaxel chemotherapy in stages II and III breast cancer［J］.Eur J Surg Oncol,2009,35(6)：583-587.